异动解读｜康方生物盘中上涨3.03%，依沃西胆道癌III期达主要终点叠加中期业绩发布日催化

行情直击08-27 09:43

8月27日，康方生物盘中上涨3.03%，报97.05港元，成交额1.65亿港元。

消息面上，公司于8月26日公告依沃西联合化疗对比度伐利尤联合化疗一线治疗晚期胆道癌的III期研究（HARMONi-GI1）达到总生存期主要终点，取得统计学显著和重大临床获益的阳性结果，关键次要终点无进展生存期与客观缓解率亦全部达成，共入组682例受试者。该研究系首个在胆道癌领域展现OS显著优于全球标准疗法的III期临床试验，标志着依沃西从肺癌拓展至消化道肿瘤。此外，公司中期业绩于今日盘后发布，市场关注依沃西第三适应症（一线鳞状非小细胞肺癌，8月12日获批）上市后的放量节奏与利润弹性。机构平均目标价170.79港元，普遍维持买入评级。

（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohunote.com/m/news/1133902044?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-08-27 09:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1133902044","market":"us","top_or_hot":-1,"title":"异动解读｜康方生物盘中上涨3.03%，依沃西胆道癌III期达主要终点叠加中期业绩发布日催化","media":"行情直击","content":"<p><p>8月27日，康方生物盘中上涨3.03%，报97.05港元，成交额1.65亿港元。</p><p>消息面上，公司于8月26日公告依沃西联合化疗对比度伐利尤联合化疗一线治疗晚期胆道癌的III期研究（HARMONi-GI1）达到总生存期主要终点，取得统计学显著和重大临床获益的阳性结果，关键次要终点无进展生存期与客观缓解率亦全部达成，共入组682例受试者。该研究系首个在胆道癌领域展现OS显著优于全球标准疗法的III期临床试验，标志着依沃西从肺癌拓展至消化道肿瘤。此外，公司中期业绩于今日盘后发布，市场关注依沃西第三适应症（一线鳞状非小细胞肺癌，8月12日获批）上市后的放量节奏与利润弹性。机构平均目标价170.79港元，普遍维持买入评级。</p><p>（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>异动解读｜康方生物盘中上涨3.03%，依沃西胆道癌III期达主要终点叠加中期业绩发布日催化</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n异动解读｜康方生物盘中上涨3.03%，依沃西胆道癌III期达主要终点叠加中期业绩发布日催化\n</h2>\n\n<h4 class=\"meta\">\n\n2026-08-27 09:43 北京时间&nbsp;&nbsp;&nbsp;<strong>行情直击</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>8月27日，康方生物盘中上涨3.03%，报97.05港元，成交额1.65亿港元。消息面上，公司于8月26日公告依沃西联合化疗对比度伐利尤联合化疗一线治疗晚期胆道癌的III期研究（HARMONi-GI1）达到总生存期主要终点，取得统计学显著和重大临床获益的阳性结果，关键次要终点无进展生存期与客观缓解率亦全部达成，共入组682例受试者。该研究系首个在胆道癌领域展现OS显著优于全球标准疗法的III期...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1133902044","we_media_id":"1059448697","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1133902044","pubTimestamp":1787794985,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"行情直击","introduction":"个股异动一手消息解读","home_visible":1,"id":"1059448697","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"8月27日，康方生物盘中上涨3.03%，报97.05港元，成交额1.65亿港元。消息面上，公司于8月26日公告依沃西联合化疗对比度伐利尤联合化疗一线治疗晚期胆道癌的III期研究达到总生存期主要终点，取得统计学显著和重大临床获益的阳性结果，关键次要终点无进展生存期与客观缓解率亦全部达成，共入组682例受试者。该研究系首个在胆道癌领域展现OS显著优于全球标准疗法的III期临床试验，标志着依沃西从肺癌拓展至消化道肿瘤。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"09926":"康方生物"},"translate_title":"Interpretation of the change | Kangfang Biotech rose by 3.03% in the intraday session, and Ivoxi biliary tract cancer stage III reached the primary endpoint, superimposed on the interim results release date catalysis","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"8月27日，康方生物盘中上涨3.03%，报97.05港元，成交额1.65亿港元。消息面上，公司于8月26日公告依沃西联合化疗对比度伐利尤联合化疗一线治疗晚期胆道癌的III期研究（HARMONi-GI1）达到总生存期主要终点，取得统计学显著和重大临床获益的阳性结果，关键次要终点无进展生存期与客观缓解率亦全部达成，共入组682例受试者。该研究系首个在胆道癌领域展现OS显著优于全球标准疗法的III期临床试验，标志着依沃西从肺癌拓展至消化道肿瘤。此外，公司中期业绩于今日盘后发布，市场关注依沃西第三适应症（一线鳞状非小细胞肺癌，8月12日获批）上市后的放量节奏与利润弹性。机构平均目标价170.79港元，普遍维持买入评级。（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1133902044","isCrawlerRequest":true}